Clinical Trial Update: A Pilot Study to Evaluate the Efficacy of Ariva® Silver Wintergreen, a Smoking Aversive Lozenge [Phase 1]

View source ↗

Summary

A Phase 1 pilot study evaluating the efficacy of Ariva Silver Wintergreen, a smoking aversive lozenge, for tobacco use disorder and smoking has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Smoking
• Tobacco Use Disorder

Drugs mentioned

• Ariva Silver Wintergreen (smoking aversive lozenge)

Snippet

Sponsor: Star Scientific, Inc | Conditions: Tobacco Use Disorder, Smoking | Phase 1 | Status: COMPLETED